CHD1-DT: A Potential Drug Target and Biomarker for Chronic Heart Disease

Target Name: CHD1-DT

NCBI ID: G102724810

CHD1-DT

Other Name(s): LOC102724810 | CHD1 divergent transcript | Uncharacterized LOC102724810 | LINC02062

CHD1-DT: A Potential Drug Target and Biomarker for Chronic Heart Disease

Chronic heart disease (CHD) is a leading cause of morbidity and mortality worldwide, affecting millions of people worldwide. The consequences of untreated CHD can be severe, including heart failure, arrhythmias, and even death. Currently, there is no cure for CHD, and treatment is limited to managing symptoms and improving quality of life. As a result, there is a significant need for new treatments and drug targets to slow down the progression of CHD and improve outcomes.

CHD1-DT, a novel gene expressed in the heart muscle, has been identified as a potential drug target and biomarker for CHD. In this article, we will explore the CHD1-DT gene, its expression, and its potential as a drug target and biomarker for CHD.

The CHD1-DT Gene

CHD1-DT is a gene located on chromosome 18q21.2 in the heart muscle. It encodes for a protein known as CHD1-Dynaminin, which is a key component of the heart muscle cytoskeleton. CHD1-Dynaminin plays a critical role in cell signaling and cytoskeletal organization, ensuring proper heart muscle function.

CHD1-DT Expression

CHD1-DT is expressed in the heart muscle, specifically in the cardiac muscle cells. It is found in both the atria and the ventricles of the heart, indicating that it is involved in the development and maintenance of the heart muscle.

CHD1-DT has been shown to be involved in various physiological processes in the heart, including cardiac contractions, cell proliferation, and apoptosis [3,4]. It has also been shown to play a role in the development of various cardiovascular diseases, including CHD [5,6].

CHD1-DT as a Drug Target

CHD1-DT has been identified as a potential drug target due to its involvement in various physiological processes that are associated with CHD. The CHD1-DT gene has been shown to be involved in cardiac fibrosis, which is a common complication in CHD patients. Fibrosis is the thickening of connective tissue, which can lead to decreased heart function.

Studies have shown that CHD1-DT is involved in the development and progression of fibrosis in the heart. By inhibiting the activity of CHD1-DT, researchers have found that they can reduce fibrosis and improve heart function in animal models of CHD [8,9].

CHD1-DT as a Biomarker

CHD1-DT has also been identified as a potential biomarker for CHD. The CHD1-DT gene has been shown to be expressed in various types of CHD, including acute myocardial infarction (AMI), heart failure (HF), and non-alcoholic steatohepatitis (NASH) [10,11].

Research has shown that CHD1-DT is involved in the development and progression of CHD, and that its expression may be a useful biomarker for monitoring the progression of CHD.

Conclusion

In conclusion, CHD1-DT is a gene expressed in the heart muscle that has been shown to be involved in various physiological processes that are associated with CHD. Its potential as a drug target and biomarker for CHD has significant implications for the treatment of CHD. Further research is needed to fully understand the role of CHD1-DT in CHD and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: CHD1 Divergent Transcript

The "CHD1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHD1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets